Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2009

Open Access 01-12-2009 | Short report

EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier

Authors: Brady Beltran, Renzo Salas, Pilar Quiñones, Domingo Morales, Fernando Hurtado, Esther Cotrina, Luis Riva, Jorge Castillo

Published in: Infectious Agents and Cancer | Issue 1/2009

Login to get access

Abstract

The development of B-cell lymphomas has been seldom described in HTLV-1 carriers. We present the case of an elderly Peruvian HTLV-1 carrier who was diagnosed with EBV-positive diffuse large B-cell lymphoma. Despite an initial good response to therapy, patient died during treatment due to fatal Pneumocystis jirovecci pneumonia. EBV infection is characterized by B-cell lymphotropism and selective immunodeficiency. HTLV-1, on the other hand, induces T-cell dysfunction and B-cell proliferation. Finally, immunosenescence is characterized by T-cell dysregulation, decreased apoptosis and cytokine upregulation. In this elderly patient, the combination of EBV and HTLV-1 coinfection and immunosenescence may have played a role in the development of this aggressive diffuse large B-cell lymphoma. Furthermore, the immunodeficiency caused by the viral infections and chemotherapy may have played a role in developing life-threatening infectious complications.
Appendix
Available only for authorised users
Literature
1.
2.
Yu GH, Montone KT, Frias-Hidvegi D, Cajulis RS, Brody BA, Levy RM: Cytomorphology of primary CNS lymphoma: review of 23 cases and evidence for the role of EBV. Diagn Cytopathol. 1996, 14: 114-120. 10.1002/(SICI)1097-0339(199603)14:2<114::AID-DC3>3.0.CO;2-J.PubMedCrossRef
3.
Siu LL, Chan JK, Kwong YL: Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002, 17: 539-554.PubMed
4.
Castillo J, Pantanowitz L, Dezube BJ: HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008, 83: 804-809. 10.1002/ajh.21250.PubMedCrossRef
5.
Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS: Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991, 337: 320-322. 10.1016/0140-6736(91)90943-J.PubMedCrossRef
6.
Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, et al.: The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007, 110: 972-978. 10.1182/blood-2007-01-067769.PubMedCrossRef
7.
Swerdlow S, Campo E, Harris N, Jaffe E: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, Lyon, France: International Agency for Research on Cancer, 4
8.
Beltran B, Morales D, Quinones P, Salas A, Riva L, Carrasco A: Distribution and Pathology Characteristics of Non Hodgkin Lymphoma in Peru: A Study of 1014 Cases Using WHO Classification of Lymphoid Neoplasm. ASH Annual Meeting Abstracts. 2007, 110: 4419-
9.
Ohshima K, Kikuchi M, Masuda Y, Sumiyoshi Y, Eguchi F, Mohtai H, Takeshita M, Kimura N: Human T-cell leukemia virus type I associated lymphadenitis. Cancer. 1992, 69: 239-248. 10.1002/1097-0142(19920101)69:1<239::AID-CNCR2820690139>3.0.CO;2-#.PubMedCrossRef
10.
Alarcon JO, Friedman HB, Montano SM, Zunt JR, Holmes KK, Quinnan GV: High endemicity of human T-cell lymphotropic virus type 1 among pregnant women in peru. J Acquir Immune Defic Syndr. 2006, 42: 604-609. 10.1097/01.qai.0000221680.52563.d5.PubMedPubMedCentralCrossRef
11.
Thompson MP, Kurzrock R: Epstein-Barr virus and cancer. Clin Cancer Res. 2004, 10: 803-821. 10.1158/1078-0432.CCR-0670-3.PubMedCrossRef
12.
Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, et al.: Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007, 13: 5124-5132. 10.1158/1078-0432.CCR-06-2823.PubMedCrossRef
13.
Buisson M, Morand P, Genoulaz O, Bourgeat MJ, Micoud M, Seigneurin JM: Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection. J Gen Virol. 1994, 75 (Pt 2): 431-437. 10.1099/0022-1317-75-2-431.PubMedCrossRef
14.
Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F: The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol. 1995, 146: 1113-1120.PubMedPubMedCentral
15.
de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, Rickinson AB, Masucci MG: T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med. 1994, 179: 1297-1305. 10.1084/jem.179.4.1297.PubMedCrossRef
16.
Kanno H, Kojya S, Li T, Ohsawa M, Nakatsuka S, Miyaguchi M, Harabuchi Y, Aozasa K: Low frequency of HLA-A*0201 allele in patients with Epstein-Barr virus-positive nasal lymphomas with polymorphic reticulosis morphology. Int J Cancer. 2000, 87: 195-199. 10.1002/1097-0215(20000715)87:2<195::AID-IJC6>3.0.CO;2-0.PubMedCrossRef
17.
Manel N, Battini JL, Sitbon M: Human T cell leukemia virus envelope binding and virus entry are mediated by distinct domains of the glucose transporter GLUT1. J Biol Chem. 2005, 280: 29025-29029. 10.1074/jbc.M504549200.PubMedCrossRef
18.
Yoshida M: Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001, 19: 475-496. 10.1146/annurev.immunol.19.1.475.PubMedCrossRef
19.
Kozuru M, Uike N, Muta K, Goto T, Suehiro Y, Nagano M: High occurrence of primary malignant neoplasms in patients with adult T-cell leukemia/lymphoma, their siblings, and their mothers. Cancer. 1996, 78: 1119-1124. 10.1002/(SICI)1097-0142(19960901)78:5<1119::AID-CNCR24>3.0.CO;2-4.PubMedCrossRef
20.
Beltran-Garate BE, Carrasco-Yalan AA, Lopez-Odria OM, Riva-Gonzales L, Rios H, Chumpitaz-Anchiraico G, Falcon-Lisarazo S, Navarro-M J, de Mendoza FH, Castillo-Aguirre J: Clinical Outcomes in Adult T Leukemia/Lymphoma: Report of 55 Cases from Peru. ASH Annual Meeting Abstracts. 2005, 106: 4797-
21.
Pimentel P, Beltran B, Flores D, Ferrel G, Falcon S, Vera L, Figueroa A, Portugal K, Bermudez V: Clinical characteristics of lymphomatous form of Adult T cell lymphoma-leukemia in Peru. ASCO Meeting Abstracts. 2005, 23: 6728-
22.
Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franceschi C, Passeri M, Sansoni P: Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood. 2000, 95: 2860-2868.PubMed
23.
Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G: Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008, 5: 6-10.1186/1742-4933-5-6.PubMedPubMedCentralCrossRef
24.
Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, Witkowski J, Fulbright J, Weyand CM, Goronzy JJ: The influence of age on T cell generation and TCR diversity. J Immunol. 2005, 174: 7446-7452.PubMedCrossRef
25.
Zinkernagel RM, Moskophidis D, Kundig T, Oehen S, Pircher H, Hengartner H: Effector T-cell induction and T-cell memory versus peripheral deletion of T cells. Immunol Rev. 1993, 133: 199-223. 10.1111/j.1600-065X.1993.tb01517.x.PubMedCrossRef
26.
Spaulding C, Guo W, Effros RB: Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol. 1999, 34: 633-644. 10.1016/S0531-5565(99)00033-9.PubMedCrossRef
27.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, et al.: Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007, 128: 92-105. 10.1016/j.mad.2006.11.016.PubMedCrossRef
28.
Murata T, Nakamura S, Kato H, Yatabe Y, Shiraishi T, Kuroda M, Yatani R, Suchi T: Epstein-Barr virus-related Hodgkin's disease showing B cell lineage in an immunosuppressive patient seropositive for HTLV-I. Pathol Int. 1997, 47: 801-805. 10.1111/j.1440-1827.1997.tb04461.x.PubMedCrossRef
29.
Sadahira Y, Nishihara H, Shimizu M, Hirokawa M, Wada H, Yamada O, Yawata Y, Manabe T: Epstein-Barr virus-associated Hodgkin's disease in HTLV-I seropositive patients: a report of two cases. Pathol Int. 1998, 48: 67-73. 10.1111/j.1440-1827.1998.tb03831.x.PubMedCrossRef
30.
Tobinai K, Ohtsu T, Hayashi M, Kinoshita T, Matsuno Y, Mukai K, Shimoyama M: Epstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia-lymphoma. Leuk Res. 1991, 15: 837-846. 10.1016/0145-2126(91)90468-9.PubMedCrossRef
31.
Roudier M, Lamaury I, Strobel M: Human T cell leukemia/lymphoma virus type I (HTLV-I) and Pneumocystis carinii associated with T cell proliferation and haemophagocytic syndrome. Leukemia. 1997, 11: 453-454. 10.1038/sj.leu.2400580.PubMedCrossRef
32.
Shahnaz S, Reich D, Arevalo-Valencia D, Kucinska S, Tulczynska J, Fleischman J: HTLV-1-associated adult T cell leukemia lymphoma presenting as granulomatous pneumocystis jiroveci pneumonia (PJP) and hypercalcemia. J Gen Intern Med. 2007, 22: 420-423. 10.1007/s11606-006-0047-6.PubMedPubMedCentralCrossRef
Metadata
Title
EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier
Authors
Brady Beltran
Renzo Salas
Pilar Quiñones
Domingo Morales
Fernando Hurtado
Esther Cotrina
Luis Riva
Jorge Castillo
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2009
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-4-10

Other articles of this Issue 1/2009

Infectious Agents and Cancer 1/2009 Go to the issue

Erratum

Erratum to: Antiviral therapy in acute viral hepatitis B: why and when

Short Report

No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease

Short report

Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection

Research Article

The seroprevalence of human papillomavirus by immune status and by ethnicity in London

Research Article

The sero-epidemiology of human papillomavirus among Caucasian transplant recipients in the UK

Research article

Human papillomavirus type 16 variants in cervical intraepithelial neoplasia and invasive carcinoma in San Luis Potosí City, Mexico
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits